

ARKANSAS STATE BOARD OF PHARMACY

LENORA NEWSOME, P.D., *President*

Smackover

LARRY MCGINNIS, Pharm.D., *Vice President*

Searcy

RONNIE NORRIS, P.D., *Secretary*

McGehee

BUDDY BOWDEN, P.D., *Member*

Little Rock



BOB DUFOUR, P.D., *Member*

Bentonville

LARRY AUTRY, P.D., *Member*

DeQueen

SHARON CAPPS, R.N.

Public Member – England

ROSS HOLIMAN, B.S., H. Ed.

Public Member – Little Rock

CHARLES S. CAMPBELL, PHARM.D.
EXECUTIVE DIRECTOR

Board of Pharmacy Regulation 07-02 – Compounding

Summary of the Substantive Changes

The changes will:

1. Amend subsection 07-02-0001 to generally prohibit compounding of a drug product that is essentially a copy of a commercially available FDA-approved drug product, to define low, medium, and high-risk sterile products, and to require sterility, pyrogen, and potency testing on certain high-risk sterile products.
2. Amend subsection 07-02-0002 to generally prohibit compounding of a drug product that is essentially a copy of a commercially available FDA-approved drug product and to prohibit compounding for office stock for veterinarians except for compounds to be used in life-threatening situations.